← Back to Clinical Trials
Recruiting NCT00373841
Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)
Trial Parameters
Condition Idiopathic Pulmonary Fibrosis
Sponsor University of Pittsburgh
Study Type OBSERVATIONAL
Phase N/A
Enrollment 500
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2005-10
Completion 2030-07
Brief Summary
The purpose of the study is to identify genetic and biologic markers that may predict the loss of lung function due to idiopathic pulmonary fibrosis. The studies will compare genetic and biologic markers of samples to changes in symptoms. The ultimate goal is to predict if or when patients are likely to experience a rapid decline in lung function due to disease progression.
Eligibility Criteria
Inclusion Criteria: * Patients who are 18 or older * Diagnosis of Idiopathic Pulmonary Fibrosis * Treated at the Simmons Center Exclusion Criteria: * Other Lung Illness
Related Trials
NCT06241560
A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amou
View Trial →
NCT07225296
A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics an
View Trial →
NCT06189820
Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases
View Trial →